EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitZurückgezogene PublikationOpen Access · CC BY 4.0

The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs

Yanbai Li, Shanshan Huo, Zhe Yin, Zuguang Tian, Fang Huang, Peng Liu, Yue Liu iD, Fei Yu iD

mBio · 2023

DOI: 10.1128/mbio.01273-23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift mBio, 2023. Verfasst von Yanbai Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Key Laboratory of Analysis and Control of Zoonotic Pathogenic Microorganism, Hebei Wild Animal Health Center, College of Life Sciences, Hebei A…. Hauptthemen laut MEDLINE: Influenza, Human, Orthomyxoviridae. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and mortality rates. Currently, the influenza drugs recommended by the FDA are oseltamivir, zanamivir, peramivir, and baloxavir marboxil. Notably, owing to the high variability of IVs, no drug exists that can effectively treat all types and subtypes of IVs. Moreover, the current trend of drug resistance is likely to continue as the viral genome is constantly mutating. Therefore, there is an urgent need to develop drugs related to the treatment of influenza to deal with the next pandemic. Here, we summarized the cutting-edge research in mechanism of action, inhibitory activity, and clinical efficacy of drugs that have been approved and drugs that are still in clinical trials for influenza treatment. We hope this review will provide up-to-date and comprehensive information on influenza antivirals and generate hypotheses for screens and development of new broad-spectrum influenza drugs in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanOrthomyxoviridaeHumansAntiviral AgentsOseltamivirZanamivirDrug Resistance, ViralNeuraminidaseEnzyme Inhibitors

Stichwörter der Autor:innen

adverse eventantiviral drugsclinical drugsinfluenza virusmechanism of action

Substanzen

Antiviral AgentsOseltamivirZanamivirNeuraminidaseEnzyme Inhibitors

Autor:innen und Institutionen

  • Hebei Key Laboratory of Analysis and Control of Zoonotic Pathogenic Microorganism, Hebei Wild Animal Health Center, College of Life Sciences, Hebei Agricultural University , Baoding, China.
  • Baoding City Science and Technology Bureau , Baoding, China.
  • Tongzhou District Center For Animal Disease Control and Prevention , Beijing, China.
  • Department of Biochemistry and Biophysics, University of California , San Francisco, California, USA.

ORCID-Profile: Yue Liu, Fei Yu

Zitieren

APA

Li, Y., Huo, S., Yin, Z., Tian, Z., Huang, F., Liu, P., Liu, Y., & Yu, F. (2023). The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs. mBio. https://doi.org/10.1128/mbio.01273-23

Vancouver

Li Y, Huo S, Yin Z, Tian Z, Huang F, Liu P, et al. The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs. mBio. 2023. doi:10.1128/mbio.01273-23

BibTeX
@article{Li2023,
  author = {Li, Yanbai and Huo, Shanshan and Yin, Zhe and Tian, Zuguang and Huang, Fang and Liu, Peng and Liu, Yue and Yu, Fei},
  title = {The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs},
  journal = {mBio},
  year = {2023},
  doi = {10.1128/mbio.01273-23}
}
Kostenlos starten →